White matter hyperintensity progression is associated with incident probable dementia or mild cognitive impairment

Adam de Havenon1, Kevin N Sheth2, Sharon D Yeatts3

  • 1Neurology, Yale University, New Haven, Connecticut, USA adam.dehavenon@hsc.utah.edu.

Abstract

Insights

White matter hyperintensity (WMH) progression on brain MRI is linked to developing dementia or mild cognitive impairment (MCI). This study confirms WMH progression as an independent risk factor for cognitive decline.

Area of Science:

  • Neurology
  • Radiology
  • Gerontology

Background:

  • White matter hyperintensity (WMH) on brain MRI is a known risk factor for dementia and mild cognitive impairment (MCI).
  • The role of WMH progression as an independent risk factor for cognitive decline has not been extensively studied.

Purpose of the Study:

  • To investigate the association between WMH progression and the incidence of probable dementia or MCI.
  • To analyze WMH progression as an independent predictor of cognitive impairment in the SPRINT MIND trial.

Main Methods:

  • A post hoc analysis of the SPRINT MIND trial data was conducted.
  • WMH progression was assessed by the Z score difference in WMH volumes between baseline and 48-month follow-up MRIs.
  • The primary outcome was incident probable dementia or MCI, with WMH progression analyzed as both a continuous Z score and a binary threshold (≥1.4 mL).

Main Results:

  • Among 433 patients, 7.6% developed dementia/MCI over 48 months.
  • Patients with WMH progression ≥1.4 mL had a significantly higher rate of dementia/MCI (12.8%) compared to those with <1.4 mL progression (4.7%).
  • WMH progression, measured by Z score (OR 1.51) and the ≥1.4 mL threshold (OR 2.89), was significantly associated with increased odds of dementia/MCI.

Conclusions:

  • WMH progression over 48 months is significantly associated with the development of probable dementia or MCI.
  • These findings highlight WMH progression as a critical independent risk factor for cognitive decline, relevant for clinical assessment and intervention.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
693
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
188
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
272